Clean Science & Technology Ltd Q1 FY27 Earnings Analysis

- HALS sales have shown strong growth, increasing from ~350-360 tonnes per quarter eight quarters ago to over 1,000 tonnes per quarter currently, with momentum expected to build further. - Higher grades of HALS are contributing to better revenue and margins, indicating improved product mix. - No specific price hike guidance for FY27 due to evolving market conditions, but inflationary environment is favorable. - Backward integration initiatives (e.g., conversion of DHDT plant) aim to reduce import dependence and improve margins, though no utilization targets have been disclosed. - Stand-alone business volumes grew sequentially by about 8%, mostly volume-led growth. - New capex of INR 80-100 crores planned in FY27, likely in the latter half, to support growth initiatives. - Overall, FY27 growth is expected with volume ramp-up, improved efficiencies, and favorable product mix, though macro uncertainties make precise forecasts challenging.

- HALS business shows strong momentum with sales increasing from ~350-360 tonnes per quarter (8 quarters ago) to over 1,000 tonnes per quarter currently, with expectations to continue building volumes and improving margins through higher-grade products and backward integration. - FY27 capex is planned between INR 80 crores to 100 crores, focusing on debottlenecking and backward integration, expected to support margin improvement and volume ramp-up. - Hydroquinone/Catechol plant is under initial stabilization; volumes and yields are expected to improve over 1-2 quarters, contributing positively to earnings. - Pricing environment is inflationary; while price hikes are uncertain, the company benefits from inflationary conditions improving margins. - Export share in HALS has increased to 50% from 20%, improving revenue and margin profiles. - Due to geopolitical and global macro uncertainties (crude oil, China supply), FY27 outlook is cautious and dependent on external factors. - Overall, volume-led revenue growth and margin expansion expected, but management foresees a "tricky" year due to external variables.

- Capex budget for FY27 is expected to be in the range of INR 80 crores to INR 100 crores (Page 16). - There is a INR 200 crores enabling resolution passed by the Board for Clean Fino-Chem, intended for future projects including potential greenfield capex; currently in early stages, no detailed roadmap shared yet (Page 15). - Backward integration efforts ongoing for HALS intermediates by refurbishing pharma plants, expected to improve margins and reduce import dependence (Page 17). - Capex related to water treatment product (Performance 2) is pushed to September, with commercial production expected by FY28 (Page 9). - DHDT facility conversion to HALS intermediate plant to strengthen competitive edge has been completed/refurbished (Page 11). - Some new capacities being scaled up for higher grade HALS (Page 10). Overall, strategic investments focus on backward integration, new product portfolio expansion, and capacity debottlenecking.

- The company has taken an enabling resolution to invest up to INR 200 crores in Clean Fino-Chem for projects including possible greenfield capex; these are in the initial stages with no specific capex timing detailed yet. - For FY27, the capex budget is projected between INR 80 crores to INR 100 crores. - No explicit mention was made about raising new debt or equity to fund these expansions or capex during the call. - The capital infusion in the subsidiary so far stands at approximately INR 200 crores, with total subsidiary investment at INR 750 crores as of the call. - Discussions suggest internal accruals and existing resources may be used, with no direct announcement of upcoming fundraising through debt or equity noted in the transcript.

The document does not explicitly mention the current or expected order book or pending orders for Clean Science and Technology Limited. However, from the discussion and responses, the following insights are available: - The company has seen strong momentum building in HALS sales, reaching over 1,000 tonnes per quarter in Q4 FY26. - Volume growth is primarily driven by increased customer offtake and expanding exports. - Sales are largely end-to-end to consumers; contract manufacturing is not a significant part currently. - Distribution tie-ups and direct customer relationships have contributed to order growth. - Ongoing optimization and backward integration efforts indicate a focus on strengthening supply position, which may support order fulfillment. - Demand visibility exists for products like Performance Chemicals 1, though ramp-up is gradual due to process optimization. No specific quantitative data on order book or pending orders is provided.